However, in three patients with lung adenocarcinoma harboring an activating EGFR kinase mutation (EGFR p.E746_A750del, p.S768I, and p.L858R) without previous EGFR-targeted therapies, we detected seven, four, and three actionable alterations, respectively. Here, EGFR is linked to lung adenocarcinoma.